Your browser is no longer supported. Please, upgrade your browser.
ADXS Advaxis, Inc. daily Stock Chart
Advaxis, Inc.
Index- P/E- EPS (ttm)-2.99 Insider Own0.47% Shs Outstand58.74M Perf Week1.64%
Market Cap32.84M Forward P/E- EPS next Y-0.55 Insider Trans-1.07% Shs Float58.74M Perf Month-27.79%
Income-37.30M PEG- EPS next Q-0.15 Inst Own10.60% Short Float7.08% Perf Quarter-19.58%
Sales1.20M P/S27.36 EPS this Y94.40% Inst Trans-22.27% Short Ratio0.69 Perf Half Y100.52%
Book/sh0.80 P/B0.70 EPS next Y8.30% ROA-73.60% Target Price5.00 Perf Year-90.32%
Cash/sh- P/C- EPS next 5Y- ROE-86.00% 52W Range0.21 - 10.80 Perf YTD-34.83%
Dividend- P/FCF- EPS past 5Y40.40% ROI-49.70% 52W High-94.82% Beta3.21
Dividend %- Quick Ratio9.30 Sales past 5Y83.60% Gross Margin- 52W Low172.55% ATR0.09
Employees35 Current Ratio9.30 Sales Q/Q-100.00% Oper. Margin- RSI (14)42.21 Volatility13.96% 15.22%
OptionableNo Debt/Eq0.00 EPS Q/Q-105.50% Profit Margin- Rel Volume0.14 Prev Close0.59
ShortableYes LT Debt/Eq0.00 EarningsMar 17 AMC Payout- Avg Volume6.04M Price0.56
Recom2.00 SMA20-14.74% SMA50-33.52% SMA200-27.94% Volume827,382 Change-5.25%
Aug-03-16Reiterated Barclays Overweight $15 → $20
Sep-22-15Initiated Barclays Overweight $40
Sep-11-15Initiated Guggenheim Buy $30
Jun-16-15Reiterated H.C. Wainwright Buy $25 → $30
May-15-15Initiated Jefferies Buy $27
May-14-15Initiated MLV & Co Buy $34
Oct-23-14Initiated H.C. Wainwright Buy $8
Feb-18-14Initiated Aegis Capital Buy $18
Feb-10-14Initiated Noble Financial Buy $12
Mar-13-20 09:00AM  Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update GlobeNewswire
Mar-03-20 04:01PM  Advaxis to Present at the 2020 LD Micro Virtual Conference GlobeNewswire -6.64%
Feb-27-20 09:00AM  Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference GlobeNewswire -13.47%
Feb-20-20 08:00AM  Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting GlobeNewswire
Feb-16-20 03:03PM  The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions Benzinga
Feb-13-20 08:00AM  Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium GlobeNewswire
Feb-11-20 08:00AM  Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program GlobeNewswire
Jan-30-20 09:23AM  Data on Advaxis Clinical Programs to be Presented at Upcoming Medical Meetings GlobeNewswire +33.54%
Jan-21-20 08:30AM  Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering GlobeNewswire -14.05%
Jan-07-20 08:00AM  Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer GlobeNewswire +21.50%
Dec-22-19 05:08PM  Is Advaxis, Inc. (ADXS) A Good Stock To Buy? Insider Monkey
Dec-20-19 08:00AM  Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update Business Wire
05:04AM  Did Changing Sentiment Drive Advaxis's (NASDAQ:ADXS) Share Price Down A Disastrous 99%? Simply Wall St.
Dec-04-19 08:00AM  Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference Business Wire
Dec-03-19 08:00AM  Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer Business Wire -8.48%
Oct-24-19 09:00AM  Advaxis Announces Business and Pipeline Update Business Wire -5.46%
Oct-10-19 08:00AM  Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research Business Wire -16.81%
Oct-07-19 08:00AM  Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial Business Wire +13.35%
Sep-19-19 06:36AM  Is This A Catalyst To Buy Advaxis, Inc. (NASDAQ:ADXS)? Simply Wall St. -15.77%
Sep-10-19 07:36AM  The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris Benzinga
Sep-09-19 08:00AM  Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update Business Wire -10.47%
Aug-22-19 08:00AM  Advaxis, Inc. Issues Letter to Shareholders Business Wire
Aug-12-19 06:30AM  BriaCell Appoints Richard J. Berman to Board of Directors GlobeNewswire
Jul-25-19 11:30AM  Advaxis, Inc. Announces Closing of $17 Million Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option Business Wire -12.43%
Jul-24-19 07:08AM  The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index Benzinga +10.00%
Jul-23-19 08:30AM  Advaxis, Inc. Announces Pricing of $16 Million Public Offering Business Wire -23.91%
Jul-15-19 08:00AM  New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies Business Wire
Jun-27-19 06:50AM  Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study Business Wire -6.67%
Jun-21-19 10:14AM  Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMT Thomson Reuters StreetEvents
Jun-11-19 09:00AM  Advaxis, Inc. to Host Earnings Call ACCESSWIRE -8.21%
Jun-10-19 04:05PM  Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update Business Wire
Jun-04-19 08:00AM  Advaxis to Host Business Update Conference Call on June 11, 2019 Business Wire +8.24%
May-25-19 09:48AM  What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)? Simply Wall St.
May-15-19 10:25AM  Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug Benzinga
08:00AM  FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac Business Wire
May-14-19 09:00AM  Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference Business Wire
May-13-19 03:00PM  Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer Business Wire -7.40%
May-07-19 09:00AM  Advaxis to Participate in Five Upcoming Industry Conferences Business Wire
Apr-18-19 05:45PM  Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know Zacks
Apr-16-19 10:54AM  QIAGEN Drives Molecular Diagnostics Suite With New Test Kit Zacks
Apr-10-19 08:43AM  Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session Zacks
Apr-08-19 09:30AM  Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year? Zacks
Apr-03-19 04:31PM  Why Range Resources, Advaxis, and StoneCo Slumped Today Motley Fool -31.36%
08:19AM  The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings Benzinga
07:44AM  Advaxis' stock plummets after public offering prices at deep discount MarketWatch
07:30AM  Advaxis Announces Pricing of Its Public Offering of Common Stock Business Wire
Apr-02-19 04:05PM  Advaxis, Inc. Announces Proposed Public Offering of Common Stock Business Wire -9.37%
09:44AM  Advaxis Up on Positive Early-Stage Immunotherapy Study Data Zacks
Apr-01-19 04:31PM  Why Wynn Resorts, Advaxis, and Roku Jumped Today Motley Fool +10.15%
03:18PM  Why Advaxis Stock Skyrocketed 13.8% Today Motley Fool
02:27PM  Advaxis Shares Surge After Positive Clinical Trial Updates Benzinga
12:20PM  Reverse Split and New Clinical Data, What's Next for Advaxis? ACCESSWIRE
12:11PM  Biotech News: Why Advaxis Stock Is Soaring Today InvestorPlace
08:00AM  ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer Business Wire
Mar-30-19 09:32AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs Benzinga
Mar-29-19 03:00PM  Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity Business Wire
Mar-28-19 01:00PM  Advaxis Announces Reverse Stock Split Business Wire -14.54%
10:41AM  Top Ranked Momentum Stocks to Buy for March 28th Zacks
Mar-27-19 10:54AM  Top Ranked Momentum Stocks to Buy for March 27th Zacks -6.15%
Mar-25-19 09:25AM  Top Ranked Momentum Stocks to Buy for March 25th Zacks +5.00%
08:00AM  Advaxis Granted U.S. Patent Relating to Axalimogene Filolisbac Business Wire
Mar-22-19 09:30AM  Has Advaxis (ADXS) Outpaced Other Medical Stocks This Year? Zacks
Mar-13-19 03:00PM  These Four Healthcare Stocks Are Making Moves on Wednesday ACCESSWIRE +22.64%
08:45AM  Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher Zacks
Mar-12-19 08:13AM  Advaxis: Fiscal 1Q Earnings Snapshot Associated Press +23.92%
08:00AM  Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update Business Wire
Mar-11-19 08:00AM  Advaxis Announces Presentations of ADXS-NEO and ADXS-PSA Data at Upcoming American Association for Cancer Research Annual Meeting Business Wire
Feb-20-19 10:51AM  Advaxis (ADXS) Upgraded to Buy: Here's What You Should Know Zacks
Feb-14-19 08:30AM  Advaxis Announces Enrollment of the First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer Business Wire
Feb-12-19 01:10PM  How Financially Strong Is Advaxis, Inc. (NASDAQ:ADXS)? Simply Wall St.
Feb-06-19 08:30AM  Advaxis Presents an Overview of its Lm Platform and Neoantigen-Directed Programs at the Immuno-Oncology 360° Conference Business Wire +20.05%
Jan-31-19 12:34PM  Edited Transcript of ADXS earnings conference call or presentation 15-Jan-19 4:00pm GMT Thomson Reuters StreetEvents +11.44%
Jan-30-19 07:35AM  New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire -5.53%
Jan-28-19 08:05AM  Advaxis to Present an Overview of its Lm Platform and New Information on its Neoantigen-Directed Therapy Programs at the Immuno-Oncology 360° Conference Business Wire
Jan-25-19 08:05AM  Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines Business Wire +17.46%
Jan-24-19 10:00AM  Immunomodulation Bolsters Scientific Advisory Board with Appointments of Robert G. Petit, Ph.D. and Rex Chin-Wei Yung, M.D., F.C.C.P. GlobeNewswire
07:45AM  The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial Benzinga
Jan-23-19 04:05PM  Advaxis Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests Business Wire -10.09%
Jan-11-19 08:38AM  The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA Benzinga -15.56%
Jan-10-19 05:25PM  Advaxis (ADXS) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM  Advaxis Reports Fiscal Year 2018 Financial Results and Provides a Business Update Business Wire
Jan-08-19 08:00AM  Advaxis to Host Business Update Conference Call on January 15, 2019 Business Wire -15.11%
Dec-12-18 10:30AM  Will Advaxis (ADXS) Report Negative Earnings Next Week? What You Should Know Zacks
08:59AM  Could Advaxis, Inc.s (NASDAQ:ADXS) Investor Composition Influence The Stock Price? Simply Wall St.
Nov-28-18 08:00AM  Advaxis to Present at LD Micro Main Event Business Wire +6.16%
Nov-06-18 08:00AM  Advaxis to Present Poster Entitled Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy at Society for Immunotherapy of Cancer Annual Meeting Business Wire +9.19%
Nov-02-18 08:00AM  Advaxis Provides Update on Clinical Pipeline Business Wire
Oct-26-18 08:00AM  Advaxis to Host Business Update Conference Call on November 2, 2018 Business Wire +10.22%
Oct-18-18 09:25AM  Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Sep-25-18 08:00AM  Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-12-18 08:26AM  The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt Benzinga
Sep-11-18 12:00PM  Advaxis Inc (NASDAQ:ADXS): How Much Growth Is Left In Healthcare? Simply Wall St. -11.09%
09:20AM  Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants Business Wire
08:25AM  The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet Benzinga
Sep-10-18 04:35PM  Advaxis: Fiscal 3Q Earnings Snapshot Associated Press -6.25%
04:30PM  Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results Business Wire
Sep-07-18 09:25AM  Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants Business Wire -28.67%
07:55AM  The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering Benzinga
Sep-06-18 05:08PM  Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants Business Wire -5.92%
Sep-04-18 08:00AM  Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma Business Wire
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
APPEL RONIDirectorMar 13Sale0.552,4011,32110,476Mar 16 05:00 PM
APPEL RONIDirectorMar 12Sale0.5820011612,877Mar 16 05:00 PM
APPEL RONIDirectorMar 11Sale0.6739926713,077Mar 16 05:00 PM
APPEL RONIDirectorApr 10Buy3.803,00011,39113,476Apr 11 12:11 PM